AstraZeneca PLC (AZN) is next scheduled to report earnings on Jul 27, 2026 (before market open). The consensus analyst EPS estimate for the upcoming quarter is $2.50.
Heading into this report, the model's fair value estimate sits 1.7% below the current price (model fair value differential below current price). Descriptive context only — not a forecast of the earnings result.
Equity Rank computed model fair value for AZN from 10 independent valuation methods with sufficient data. 3 place fair value above the current price of $173.11, and 7 place it below. The model-blended estimate lands at $170.19 — a model fair value differential of 1.7% below the current price under these model assumptions. The larger group places fair value below the current price.
Equity Rank's fundamental strength composite scores AZN at 78.6/100 (A-, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +6.2% per year and gross margin has moved +9.8 pp. Its SAVE composite score has moved +0.5 over the past 30 days.
AstraZeneca PLC (AZN) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks